Results of Phase 2 studies of zerlasiran and muvalaplin in patients with elevated Lp(a) and atherosclerotic cardiovascular disease (ASCVD) have been published.1,2
Other articles available on Lp(a) Forum
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.